We illustrate an acute retinal toxicity from oral Entecavir (Bristol-Myers-Squibb, USA) as treatment for acute hepatitis-B infection, and subsequent reversal of retinal toxicity upon stopping Entecavir with full restoration of visual functions.
Case report
A 52-year-old Caucasian male presented with unilateral sudden painless reduced vision and central scotoma of 5-day duration. Patient was diagnosed acute hepatitis-B infection 6 weeks before and was started with oral Entecavir 0.5 mg once daily. His presenting vision was 6/15OS and 6/6OD, normal pupillary reactions, full colour-perception and no ocular inflammation. Right fundus was normal while left showed mildly hyperaemic optic disc and a central well-demarcated hypopigmented area in posterior pole ( Fig. 1: 1A) . Both fundusfluorescein angiography ( Fig. 1 ) and optical coherence tomography ( Fig. 2 ) depicted corresponding retinal pigment epithelial (RPE) and photoreceptors abnormality. He had also established patchy central Goldmann field defects and grossly reduced full-field electroretinogram (delayed responses from both rod and cones) in OS only. Excluded retinovasculitis and satisfactory normal systemic investigations, a suspicion of drug toxicity was made. Entecavir was stopped immediately and remained off when his liver function test was also normalised. At 2-month review, his vision had reached 6/6, centre RPE hypopigmentation became indistinct. By 5 months, all visual function tests and fundoscopy were fully restored (Figs. 1, and 2 ).
* Peck Lin Lip pllipwoo@gmail.com Entecavir is an anti-viral drug commonly used in treatment of hepatitis-B infection but there was no recognised ocular toxicity in its association [1] [2] [3] . The mechanism of retinal toxicity remains unclear with lacking histopathological studies. There was a published case report with irreversible blindness when on year(s) of Entecavir complicated by diabetic retinopathy at the time of suspected retinal toxicity [4] . Our case shared similar clinical features as their reported second eye. Notably, Entecavir drug toxicity is causing sequential rather than bilateral simultaneous eye manifestations. Our patient's left eye was profoundly involved but his right eye had not progressed more than the minimal peripheral vascular staining in late fundus photographs and fluorescein angiography phase ( Fig. 1: 2A) .
Our case confirmed short-term Entecavir use could cause reversible retinal toxicity upon drug cessation. Prescribing physicians and ophthalmologists should be aware of the potential retinal toxicity of Entecavir. We reported this adverse drug reaction to the UK Medicines and Health Products Regulatory Agency. Compliance with ethical standards
